OS Therapies Incorporated (OSTX)

OS Therapies' stock has been influenced by regulatory progress for OST-HER2, including submissions and meetings with regulatory agencies, which often correlated with positive stock price movement. The company reported a net operating loss for 2025 and raised capital in Q1 2026, but the stock declined due to persistent unprofitability. OS Therapies acquired listeria monocytogenes platform assets and secured patent extensions. Analysts maintain a 'Buy' rating with price targets suggesting significant upside. A major shareholder sold shares, and short interest decreased, while an investigation was launched into the company's directors' fiduciary duties.

OS Therapies' stock exhibits demand seasonality, with April historically showing the highest probability of positive returns, while March has shown a 0.00% probability of positive returns. This seasonality refers to stock performance rather than direct demand for its clinical-stage products.

OS Therapies, Inc. is a clinical-stage oncology and biopharmaceutical company focused on developing innovative treatments for osteosarcoma and other solid tumors, operating within the Biotechnology industry. Their lead product, OST-HER2, is an immunotherapy targeting HER2-expressing cancer cells and has received multiple designations from the FDA and EMA. The company also has a next-generation tunable Antibody Drug Conjugate platform and is developing OST-HER2 for canine osteosarcoma.

OS Therapies is headquartered in Grasonville and Rockville, Maryland, with a primary focus on the U.S. market. The company is also pursuing regulatory approvals in the UK, Europe, and Australia for OST-HER2, indicating an expanding international presence.

OS Therapies' brand reputation has been influenced by a 'Moderate Buy' rating from analysts and positive news sentiment. A documentary featuring OST-HER2-treated patients received Emmy nominations. However, an investigation into the company's directors' fiduciary duties could negatively impact the company's reputation and stock price.

OS Therapies has a diverse ownership structure including institutional, individual, and retail investors. Institutional shareholders own 5.04% of the company, insiders own 18.78%, and retail investors hold 76.18%. Major institutional owners include Vanguard Group Inc and BlackRock, Inc. Shalom Auerbach is the largest individual shareholder.